Santiago-O'Farrill Janice M, Kleinerman Eugenie S, Hollomon Mario G, Livingston Andrew, Wang Wei-Lien, Tsai Jen-Wei, Gordon Nancy B
Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Biology, Texas Southern University, Houston, Texas, USA.
Oncotarget. 2017 Aug 17;9(2):1602-1616. doi: 10.18632/oncotarget.20308. eCollection 2018 Jan 5.
Autophagy is a catabolic process involved in cellular homeostasis. Autophagy is increased above homeostatic levels by chemotherapy, and this can either promote or inhibit tumor growth. We previously demonstrated that aerosol gemcitabine (GCB) has a therapeutic effect against osteosarcoma (OS) lung metastases. However, some tumor cells failed to respond to the treatment and persisted as isolated lung metastasis. Here, we examined the mechanisms underlying the dual role of chemotherapy-induced autophagy in OS and sought to identify biomarkers to predict OS response to treatment. In this study, we demonstrate that treatment of various OS cells with GCB induced autophagy. We also showed that GCB reduces the phosphorylation of AKT, mTOR and p70S6K and that GCB-induced autophagy in OS can lead to either cell survival or cell death. Blocking autophagy enhanced the sensitivity of LM7 OS cells and decreased the sensitivity of CCH-OS-D and K7M3 OS cells to GCB. Using a kinase array, we also demonstrated that differences in the phosphorylated heat shock protein 27 (p-HSP27) expression in the various OS cell lines after treatment with GCB, correlates to whether chemotherapy-induced autophagy will lead to increase or decrease OS cells sensitivity to therapy. Increased p-HSP27 was associated with increased sensitivity to anticancer drug treatment when autophagy is inhibited. The results of this study reveal a dual role of autophagy in OS cells sensitivity to chemotherapy and suggest that p-HSP27 could represent a predictive biomarker of whether combination therapy with autophagy modulators and chemotherapeutic drugs will be beneficial for OS patients.
自噬是一种参与细胞稳态的分解代谢过程。化疗可使自噬增加至稳态水平以上,这既可以促进也可以抑制肿瘤生长。我们之前证明,雾化吉西他滨(GCB)对骨肉瘤(OS)肺转移具有治疗作用。然而,一些肿瘤细胞对该治疗无反应,并以孤立的肺转移灶形式持续存在。在此,我们研究了化疗诱导的自噬在OS中的双重作用机制,并试图确定预测OS对治疗反应的生物标志物。在本研究中,我们证明用GCB处理各种OS细胞可诱导自噬。我们还表明,GCB可降低AKT、mTOR和p70S6K的磷酸化水平,并且GCB在OS中诱导的自噬可导致细胞存活或细胞死亡。阻断自噬增强了LM7 OS细胞的敏感性,并降低了CCH-OS-D和K7M3 OS细胞对GCB的敏感性。使用激酶阵列,我们还证明,用GCB处理后,各种OS细胞系中磷酸化热休克蛋白27(p-HSP27)表达的差异与化疗诱导的自噬是否会导致OS细胞对治疗的敏感性增加或降低相关。当自噬被抑制时,p-HSP27增加与对抗癌药物治疗的敏感性增加相关。本研究结果揭示了自噬在OS细胞对化疗敏感性中的双重作用,并表明p-HSP27可能代表自噬调节剂与化疗药物联合治疗对OS患者是否有益的预测生物标志物。